On November 24, 2025 Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, reported it will present 10 abstracts across its Precision Oncology portfolio at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place from December 9-12 in San Antonio, Texas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data to be presented builds upon Exact Sciences’ long-standing commitment to backing innovation with strong clinical evidence and commitment to equitable breast cancer care. This commitment includes equipping clinicians with innovative solutions that provide actionable insights to support patient needs throughout every stage of cancer care.
"Oncotype DX has long set a global standard as a predictive and prognostic test in breast cancer, helping clinicians confidently guide therapy decisions that improve outcomes and reduce disparities," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "The data presented at this year’s SABCS reaffirms our leadership in breast cancer prediction and prognosis and expands our evidence base for Oncodetect—our molecular residual disease test—as a powerful recurrence predictor and tool for personalizing surveillance in high-risk patients."
Data presentations across Exact Sciences’ Precision Oncology portfolio include:
The Oncodetect Test
Title: Evaluation of a Whole-Exome Sequencing Tumor-informed Circulating Tumor DNA MRD Assay in Patients with Early Triple-Negative Breast Cancer (TNBC) receiving Neoadjuvant Chemotherapy (NAC) with or without Atezolizumab: A Prospective Sub-study of the NSABP-B59/GBG-96-GeparDouze Trial
In partnership with the National Surgical Adjuvant Breast and Bowel Project (NSABP), this sub-study evaluated MRD in patients with triple-negative breast cancer (TNBC) and demonstrated the strong predictive performance of the Oncodetect test using prospectively collected samples from a Phase III randomized trial.
Session: RF4-03, Thursday, December 11, 2025; 4:30-5:30 PM
Title: Prospective Breast Cancer Clinical Validation Study of an Ultrasensitive, Tumor Informed, Whole Genome, Circulating Tumor DNA Assay to Detect Molecular Residual Disease and Predict Recurrence of High-Risk Early Breast Cancer Treated with Standard (Neo)adjuvant Therapy; NSABP B-64/EXActDNA-003NCT06401421
Conducted in collaboration with the NSABP, this large-scale, ongoing trial is enrolling more than 1,800 participants across all breast cancer subtypes. Tracking patients from diagnosis through treatment and post-therapy surveillance, the study will deliver multiple readouts beginning in 2027 that will further expand the clinical evidence supporting the Oncodetect test.
Session: PS5-08-21, Friday December 12, 2025; 12:30-2:00 PM
Title: Early Adoption of Molecular Residual Disease Testing in Breast Cancer Patients using Real World Data
This real-world data analysis of MRD adoption trends in breast cancer highlights the increasing use and integration of these tests into clinical practice.
Session: PS2-04-01, Thursday, December 11, 2025; 5:00-6:30 PM
The Oncotype DX Breast Recurrence Score Test
Title: Clinical and economic impact of the 21-gene assay for guiding treatment in patients with HR+/HER2- early breast cancer across racial and ethnic subgroups in the US
Study confirms that utilization of the Oncotype DX Breast Recurrence Score test to guide adjuvant therapy decision-making can lead to improved outcomes and reduce costs across diverse racial and ethnic subgroups, highlighting the potential of the assay to support more equitable care and reduce outcome disparities.
Session: PS4-09-24, Thursday, December 11, 2025; 5:00-6:30 PM
Title: Real-world utilization of the 21-gene assay for guiding treatment decisions in patients with HR+/HER2- early breast cancer in the US
Analysis demonstrates that the Oncotype DX Breast Recurrence Score test reliably guides adjuvant chemotherapy with utilization rising appropriately with higher scores and applied consistently across racial and ethnic groups, confirming equitable, guideline‑concordant treatment patterns highlighting the test’s impact in standardizing care decisions.
Session: PS2-06-21, Wednesday, December 10, 2025, 5:00-6:30 PM
Title: Real-world evidence on the use of a 21-gene recurrence score assay in patients with HR+/HER2− early breast cancer in Japan: a nationwide claims database analysis
First large-scale study of the Oncotype DX test in Japan confirmed that patients are treated at cancer-specialized or large medical centers and staging/treatment patterns show appropriate application of the Oncotype DX test in HR+/HER2 early breast cancer, consistent with current guidelines.
Session: PS3-08-28, Thursday, December 11, 2025; 12:30-2:00 PM
Title: Decision-Making on Adjuvant Chemotherapy in Early HR+ Breast Cancer: A Prospective Evaluation of Oncotype DX Utility Among Swiss Breast Cancer Experts
Study found that the Oncotype DX test significantly influenced adjuvant treatment decisions—primarily driving chemotherapy de‑escalation—and improved decision consistency among breast cancer specialists, underscoring the test’s utility in the Swiss healthcare system.
Session: PS3-10-10, Thursday, December 11, 2025; 12:30-2:00 PM
Title: The Societal Cost Impact of Oncotype DX Testing in an Irish Healthcare Setting
Use of the Oncotype DX test to identify node-positive patients that could avoid chemotherapy across 5 of Ireland’s oncology centers over an 11-year period has led to an estimated cost-savings of more than 60 million euros associated with chemotherapy use.
Session: PS3-09-03, Thursday, December 11, 2025; 12:30-2:00 PM
Title: Defining postpartum breast cancer based on 21-gene recurrence score
Breast cancer diagnosed within 5 years postpartum shows significantly higher Oncotype DX Recurrence Score results and higher histologic grade than in nulliparous peers—independent of nodal status. By stratifying risk by time since childbirth, the study refines the temporal definition of postpartum breast cancer and may inform risk stratification and treatment escalation.
Session: Poster PS3-07-11, Thursday, December 11; 2025; 12:30-2:00 PM
Title: Postpartum breast cancer as a potential driver of increased 21-gene recurrence score (RS) and RS category for node-positive HR+/HER2- breast cancer
In premenopausal, node-positive HR+/HER2− breast cancer, postpartum cases show higher Oncotype DX Recurrence Score results than nulliparous or non-postpartum cases. The study examines whether this impacts outcomes (e.g., invasive disease-free survival) to refine Recurrence Score result interpretation and better identify patients who might safely forgo chemotherapy, noting that larger studies with longer follow-up are needed.
Session: PS3-08-09, Thursday, December 11, 2025; 12:30-2:00 PM
(Press release, Exact Sciences, NOV 24, 2025, View Source [SID1234660895])